Maintaining 'Buy' Rating on AC Immune's PD Trial Progress with ACI-7104.056

AC Immune maintains a "Buy" rating as the company continues to advance its ACI-7104.056 development in Parkinson's disease. The company's approach focuses on a unique mechanism of action that targets neurotoxic protein misfolding, which is a hallmark of the disease. ACI-7104.056 has shown promising results in preclinical studies and is expected to enter clinical trials soon. The analyst remains optimistic about the potential of AC Immune's pipeline and the company's ability to deliver on its clinical development milestones.